DDInter1631 DDInter1788
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+).
Tetryzoline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Guanadrel
Tetryzoline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levosalbutamol
Tetryzoline {u} may lead to a major life threatening interaction when taken with {v} Iobenguane
Tetryzoline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Methylene blue
Tetryzoline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Selegiline
Tetryzoline may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel
Tetryzoline may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Tetryzoline may lead to a major life threatening interaction when taken with Iobenguane
Tetryzoline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Tetryzoline may lead to a major life threatening interaction when taken with Methylene blue
Tetryzoline may cause a moderate interaction that could exacerbate diseases when taken with Selegiline and Tetryzoline may lead to a major life threatening interaction when taken with Selegiline